189 related articles for article (PubMed ID: 34572576)
1. CDR1 Composition Can Affect Nanobody Recombinant Expression Yields.
Orlando M; Fortuna S; Oloketuyi S; Bajc G; Goldenzweig A; de Marco A
Biomolecules; 2021 Sep; 11(9):. PubMed ID: 34572576
[TBL] [Abstract][Full Text] [Related]
2. Positive charge in the complementarity-determining regions of synthetic nanobody prevents aggregation.
Zhong Z; Yang Y; Chen X; Han Z; Zhou J; Li B; He X
Biochem Biophys Res Commun; 2021 Oct; 572():1-6. PubMed ID: 34332323
[TBL] [Abstract][Full Text] [Related]
3. ModiBodies: A computational method for modifying nanobodies in nanobody-antigen complexes to improve binding affinity and specificity.
Hacisuleyman A; Erman B
J Biol Phys; 2020 Jun; 46(2):189-208. PubMed ID: 32418062
[TBL] [Abstract][Full Text] [Related]
4. Unravelling the Molecular Basis of High Affinity Nanobodies against HIV p24: In Vitro Functional, Structural, and in Silico Insights.
Gray ER; Brookes JC; Caillat C; Turbé V; Webb BLJ; Granger LA; Miller BS; McCoy LE; El Khattabi M; Verrips CT; Weiss RA; Duffy DM; Weissenhorn W; McKendry RA
ACS Infect Dis; 2017 Jul; 3(7):479-491. PubMed ID: 28591513
[TBL] [Abstract][Full Text] [Related]
5. CDR grafting and site-directed mutagenesis approach for the generation and affinity maturation of Anti-CD20 nanobody.
Heidari MM; Shirazi EA; Cheraghi SF; Shahshahani R; Rahnama T; Khatami M
Mol Biol Rep; 2024 Jun; 51(1):751. PubMed ID: 38874667
[TBL] [Abstract][Full Text] [Related]
6. Antigen recognition by single-domain antibodies: structural latitudes and constraints.
Henry KA; MacKenzie CR
MAbs; 2018; 10(6):815-826. PubMed ID: 29916758
[TBL] [Abstract][Full Text] [Related]
7. Contributions of the complementarity determining regions to the thermal stability of a single-domain antibody.
Zabetakis D; Anderson GP; Bayya N; Goldman ER
PLoS One; 2013; 8(10):e77678. PubMed ID: 24143255
[TBL] [Abstract][Full Text] [Related]
8. Molecular dynamics simulations and docking enable to explore the biophysical factors controlling the yields of engineered nanobodies.
Soler MA; de Marco A; Fortuna S
Sci Rep; 2016 Oct; 6():34869. PubMed ID: 27721441
[TBL] [Abstract][Full Text] [Related]
9. Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions.
Perchiacca JM; Ladiwala AR; Bhattacharya M; Tessier PM
Protein Eng Des Sel; 2012 Oct; 25(10):591-601. PubMed ID: 22843678
[TBL] [Abstract][Full Text] [Related]
10. Structural insights into a high affinity nanobody:antigen complex by homology modelling.
Skottrup PD
J Mol Graph Model; 2017 Sep; 76():305-312. PubMed ID: 28779687
[TBL] [Abstract][Full Text] [Related]
11. Physicochemical determinants of antibody-protein interactions.
Karadag M; Arslan M; Kaleli NE; Kalyoncu S
Adv Protein Chem Struct Biol; 2020; 121():85-114. PubMed ID: 32312427
[TBL] [Abstract][Full Text] [Related]
12. Nanobody affinity improvement: Directed evolution of the anti-ochratoxin A single domain antibody.
Wang X; Chen Q; Sun Z; Wang Y; Su B; Zhang C; Cao H; Liu X
Int J Biol Macromol; 2020 May; 151():312-321. PubMed ID: 32084462
[TBL] [Abstract][Full Text] [Related]
13. Construction of Synthetic Nanobody Library in Mammalian Cells by dsDNA-Based Strategies*.
Zhao Y; Wang Y; Su W; Li S
Chembiochem; 2021 Oct; 22(20):2957-2965. PubMed ID: 34411391
[TBL] [Abstract][Full Text] [Related]
14. NanoNet: Rapid and accurate end-to-end nanobody modeling by deep learning.
Cohen T; Halfon M; Schneidman-Duhovny D
Front Immunol; 2022; 13():958584. PubMed ID: 36032123
[TBL] [Abstract][Full Text] [Related]
15. Recombinant expression of nanobodies and nanobody-derived immunoreagents.
de Marco A
Protein Expr Purif; 2020 Aug; 172():105645. PubMed ID: 32289357
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel anti-EGFR nanobody by phage display and its distinct paratope and epitope via homology modeling and molecular docking.
Xi X; Sun W; Su H; Zhang X; Sun F
Mol Immunol; 2020 Dec; 128():165-174. PubMed ID: 33130376
[TBL] [Abstract][Full Text] [Related]
17. Display of somatostatin-related peptides in the complementarity determining regions of an antibody light chain.
Simon PJ; Brogle KC; Wang B; Kyle DJ; Soltis DA
Arch Biochem Biophys; 2005 Aug; 440(2):148-57. PubMed ID: 16051181
[TBL] [Abstract][Full Text] [Related]
18. Studying the characteristics of nanobody CDR regions based on sequence analysis in combination with 3D structures.
Truong TTT; Huynh VQ; Vo NT; Nguyen HD
J Genet Eng Biotechnol; 2022 Nov; 20(1):157. PubMed ID: 36417012
[TBL] [Abstract][Full Text] [Related]
19. A Two-Step Approach for the Design and Generation of Nanobodies.
Wagner HJ; Wehrle S; Weiss E; Cavallari M; Weber W
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30400198
[TBL] [Abstract][Full Text] [Related]
20. Change of Amino Acid Residues in Idiotypic Nanobodies Enhanced the Sensitivity of Competitive Enzyme Immunoassay for Mycotoxin Ochratoxin A in Cereals.
Zhang C; Zhang W; Tang X; Zhang Q; Zhang W; Li P
Toxins (Basel); 2020 Apr; 12(4):. PubMed ID: 32340239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
